Pear Therapeutics Completes $80M Series D Financing Led by SoftBank Vision Fund 2
Summary
These diseases are on the rise as the pandemic has exacerbated the country’s mental health crises.4,5 Pear will use the financing to accelerate reimbursement coverage for its three commercial products, creating the first market access pathway in the PDT industry. “ Pear Therapeutics has combined biology and software to pioneer the first end-to-end platform for prescription digital products, with an initial focus on serious psychiatric diseases. We’re pleased to support Pear’s mission to create the next generation of therapeutics and deliver better patient outcomes.” In conjunction with the financing, Nancy Schlichting, retired Chief Executive Officer, Henry Ford Health System, and Board Director at Walgreens Boots Alliance and Hill-Rom Holdings, Inc., and Elena Viboch, an investor at SoftBank Investment Advisers, will join Pears Board of Directors. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician.
Funding
Review available funding amount, funding date, investors, and linked company information related to Pear Therapeutics Completes $80M Series D Financing Led by SoftBank Vision Fund 2 in the interactive ISVWorld profile.